Pro Share Advisors LLC Keros Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$42.5 Billion
Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 10,549 shares of KROS stock, worth $108,865. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,549

Previous 7,785 35.5%

Holding current value

$108,865

Previous $452,000 63.27%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$15.64 - $70.0 $43,228 - $193,480	2,764 Added 35.5%	10,549 $166,000
Q3 2024 Nov 13, 2024	BUY	$41.68 - $58.07 $88,278 - $122,992	2,118 Added 37.37%	7,785 $452,000
Q2 2024 Aug 13, 2024	SELL	$44.58 - $66.89 $65,488 - $98,261	-1,469 Reduced 20.59%	5,667 $258,000
Q1 2024 May 08, 2024	BUY	$41.26 - $70.48 $61,724 - $105,438	1,496 Added 26.52%	7,136 $472,000
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $152,956 - $231,521	5,640 New	5,640 $224,000
Q4 2022 Feb 02, 2023	BUY	$39.45 - $51.77 $187,505 - $246,062	4,753 New	4,753 $228,000
Q2 2022 Aug 01, 2022	SELL	$26.03 - $67.04 $139,234 - $358,596	-5,349 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$42.12 - $59.36 $56,988 - $80,314	-1,353 Reduced 20.19%	5,349 $291,000
Q4 2021 Feb 08, 2022	SELL	$36.95 - $62.89 $10,493 - $17,860	-284 Reduced 4.07%	6,702 $392,000
Q3 2021 Nov 12, 2021	SELL	$29.27 - $43.71 $36,528 - $54,550	-1,248 Reduced 15.16%	6,986 $276,000
Q2 2021 Aug 13, 2021	BUY	$42.4 - $70.11 $62,709 - $103,692	1,479 Added 21.89%	8,234 $350,000
Q1 2021 May 14, 2021	BUY	$54.0 - $75.28 $15,822 - $22,057	293 Added 4.53%	6,755 $416,000
Q4 2020 Feb 09, 2021	BUY	$36.0 - $82.74 $232,632 - $534,665	6,462 New	6,462 $456,000

Others Institutions Holding KROS

# of Institutions

172

Shares Held

29.9M

Call Options Held

341K

Put Options Held

102K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $266M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Keros Therapeutics, Inc. Transaction History